Trial Profile
Phase 2 Trial of PEG-ASP Combined With Etoposide and Gemcitabine (PEG) as First-line Chemotherapy to Treat NK/T-cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Pegaspargase (Primary) ; Etoposide; Gemcitabine
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- 15 Jun 2023 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 15 Jun 2023 Planned primary completion date changed from 1 Jun 2021 to 1 Dec 2023.
- 15 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.